Results 21 to 30 of about 11,689 (208)
Эпидемиология и вакцинопрофилактика, 2023 Relevance. In the Russian Federation, despite the low incidence rate in 2020–2021, there are subjects where the incidence rate of meningococcal infection (MI) exceeds the national average by 2–9 times.
V. V. Romanenko +3 more
doaj +1 more source
In vitro alternative for reactogenicity assessment of outer membrane vesicle based vaccines
Scientific Reports, 2023 Intrinsic or added immune activating molecules are key for most vaccines to provide desired immunity profiles but may increase systemic reactogenicity. Regulatory agencies require rabbit pyrogen testing (RPT) for demonstration of vaccine reactogenicity ...
Marijke W. A. Molenaar-de Backer +9 more
doaj +1 more source
Immunogenicity and Reactogenicity of CoronaVac: A Cohort Study
COVID, 2022 The ongoing COVID-19 pandemic remained a major public health concern despite a large-scale deployment of vaccines. One of the vaccines is CoronaVac, an inactivated vaccine. The efficacy of the vaccine was estimated at 50.7–83.5% in clinical trials. However, the real-world efficacy often differed.
Sri Masyeni +7 more
openaire +1 more source
Vaccines, 2021 This is the first study outside of clinical trials (phase I–III) evaluating the ability of the Ad5-nCoV vaccine to generate neutralizing antibodies and the factors associated with optimal or suboptimal response.
Jorge Hernández-Bello +8 more
doaj +1 more source
Immunopotentiation by Natural Extracts: Mechanisms and Applications in Influenza Vaccine Adjuvant Development. [PDF]
Food Sci NutrNatural Extracts as Candidate Influenza Vaccine Adjuvants. Seasonal influenza vaccines face limitations due to viral mutations and low efficacy in vulnerable populations. Traditional adjuvants often have safety or immune‐activation constraints, leading to increased interest in natural extracts from plants, marine organisms, and fungi.
Ho TL, Ko EJ.
europepmc +2 more sources
Efficacy and Safety of Messenger RNA Vaccines. [PDF]
Health Sci RepABSTRACT Background and Aims The rapid development of mRNA vaccines has revolutionized infectious disease prevention and cancer immunotherapy. While their efficacy is well established, concerns about safety and immunopathological risks persist. This study aims to evaluate the immunogenicity, safety profiles, and design considerations of mRNA vaccines ...
Batisani K, Chisompola D.
europepmc +2 more sources
Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review [PDF]
Immunologic Research, 2022 SARS-CoV-2 is an RNA virus that was identified for the first time in December 2019 in Wuhan, China. The World Health Organization (WHO) labeled the novel coronavirus (COVID-19) outbreak a worldwide pandemic on March 11, 2020, due to its widespread infectivity pattern.
Swarnali Das +5 more
openaire +2 more sources
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination [PDF]
, 2021 Heterologous priming with the ChAdOx1 nCoV-19 vector vaccine followed by boosting with a messenger RNA vaccine (BNT162b2 or mRNA-1273) is currently recommended in Germany, although data on immunogenicity and reactogenicity are not available.
Guckelmus, Candida +14 more
core +1 more source
Rubella Vaccine – How ‘Reactogenic’ is it?
Journal of International Medical Research, 1986 Girls (231) aged 11—13 years were allocated at random to receive one of two RA27/3 rubella vaccines. A high incidence of minor and self-limiting side-effects were found by intensive follow-up. No difference in reactogenicity could be found between vaccines from the Institut Merieux and Wellcome.
G V, Griffin, K A, Bryett
openaire +2 more sources